Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2020 April;111(2) > Minerva Medica 2020 April;111(2):166-72

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Medica 2020 April;111(2):166-72

DOI: 10.23736/S0026-4806.19.06395-X

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Lymphomatoid papulosis

Antonello SICA 1 , Paola VITIELLO 2, Antonio SORRIENTO 3, Andrea RONCHI 4, Armando CALOGERO 5, Caterina SAGNELLI 6, Teresa TROIANI 1, Morena FASANO 1, Concetta A. DODARO 5, Renato FRANCO 4, Beniamino CASALE 7, Michele SANTANGELO 5, Massimo CICCOZZI 8, Fortunato CIARDIELLO 1, Giuseppe ARGENZIANO 2, Elvira MOSCARELLA 2

1 Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy; 2 Unit of Dermatology, University of Campania, Naples, Italy; 3 Department of Heart Surgery and Transplantations, AO Dei Colli - V. Monaldi, Naples, Italy; 4 Division of Pathology, Department of Mental Health And Preventive Medicine, Luigi Vanvitelli University of Campania, Naples, Italy; 5 Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy; 6 Department of Mental Health and Public Medicine, Luigi Vanvitelli University of Campania, Naples, Italy; 7 Department of Pneumology And Tisiology, AO Dei Colli - V. Monaldi, Naples, Italy; 8 Unit of Medical Statistics and Molecular Epidemiology, Campus Bio-Medico University, Rome, Italy



Lymphomatoid papulosis (LyP) is a non-aggressive skin disorder characterized by papulonodular injuries, sometimes necrotic, often scattered, relapsing, which frequently regress spontaneously. LyP represents about 12% of cutaneous lymphomas. The etiology of LyP is unknown. Based on its histopathology, in 2018, the World Health Organization (WHO) classified LyP into six types with similar prognosis (A,B,C,D,E and DUSP22). Once the diagnosis of LyP has been made, having an excellent prognosis, this pathology must be managed mainly with a “watch and wait” strategy. Treatment should be given only in the presence of diffuse, symptomatic lesions with disfiguring evolution, with the aim of reducing time of resolution and preventing recurrences or the formation of new lesions.


KEY WORDS: Lymphoma, T-cell, cutaneous; Skin neoplasms; Lymphoma, T-cell

top of page